Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

The National Institute for Health and Care Excellence (NICE) has approved a one-off gene editing therapy to treat severe sickle cell disease (SCD) in people 12 years and over. In final draft guidance1 ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

AI could deliver substantially greater efficiencies in cell and gene therapy manufacturing and enable more patients to ...

NHS England & Vertex reach deal for sickle cell gene therapy Casgevy, making it available at an undisclosed reduced price ...